Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H23N3O3 |
| Molecular Weight | 293.3614 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)[C@H]1C[C@H](NC2=CC=C(C=C12)[N+]([O-])=O)C(C)(C)CO
InChI
InChIKey=YNYAUBNZRZVNLX-KBPBESRZSA-N
InChI=1S/C15H23N3O3/c1-15(2,9-19)14-8-13(17(3)4)11-7-10(18(20)21)5-6-12(11)16-14/h5-7,13-14,16,19H,8-9H2,1-4H3/t13-,14-/m0/s1
| Molecular Formula | C15H23N3O3 |
| Molecular Weight | 293.3614 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:38:07 UTC 2023
by
admin
on
Sat Dec 16 11:38:07 UTC 2023
|
| Record UNII |
TBF49WHM83
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-S-40503
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TBF49WHM83
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
PRIMARY | |||
|
DTXSID801027128
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
PRIMARY | |||
|
404920-28-1
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
PRIMARY | |||
|
1345011-36-0
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
ALTERNATIVE | |||
|
S-40503
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
PRIMARY | S-40503 is an investigational selective androgen receptor modulator (SARM) developed by the Japanese company Kaken Pharmaceuticals, which was developed for the treatment of osteoporosis. SARMs are a new class of drugs which produce tissue-specific anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in other tissues such as in the prostate gland, thus avoiding side effects such as benign prostatic hypertrophy which can occur following treatment with unselective androgens like testosterone or anabolic steroids. | ||
|
DB13938
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
PRIMARY | |||
|
57398987
Created by
admin on Sat Dec 16 11:38:07 UTC 2023 , Edited by admin on Sat Dec 16 11:38:07 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
